Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/18/2018 |
| Start Date: | October 2014 |
| End Date: | July 2020 |
| Contact: | Geoffrey Stroud, PharmD, BCOP, CPP |
| Email: | Stroudg@ecu.ecu |
INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer
There is a growing body of evidence that implicates inflammation as a mechanism of disease
progression and reduced survival in patients with advanced cancer. Elevated c-reactive
protein levels have been shown to be associated with reduced performance status, specific
cancer related symptoms and reduced overall survival. C-reactive protein levels are a
surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer
recurrence. VeriStrat® is a multivariate test which measures protein expression related to a
host/tumor interaction mediated by inflammation. The investigators hope to examine the
relationship between quality of life outcomes per FACT-L survey and correlate them with
changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study
is that the remarkable survival benefit in the Temel study is mediated by reduced
inflammation with improvement of symptom control.
progression and reduced survival in patients with advanced cancer. Elevated c-reactive
protein levels have been shown to be associated with reduced performance status, specific
cancer related symptoms and reduced overall survival. C-reactive protein levels are a
surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer
recurrence. VeriStrat® is a multivariate test which measures protein expression related to a
host/tumor interaction mediated by inflammation. The investigators hope to examine the
relationship between quality of life outcomes per FACT-L survey and correlate them with
changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study
is that the remarkable survival benefit in the Temel study is mediated by reduced
inflammation with improvement of symptom control.
Inclusion Criteria:
- Confirmed diagnosis of stage IV non-small cell lung cancer
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Able to read and respond to questions in English
Exclusion Criteria:
- Small Cell Lung Cancer
We found this trial at
1
site
Greenville, North Carolina 27834
Principal Investigator: Geoffrey C Stroud, PharmD, BCOP, CPP
Click here to add this to my saved trials
